New class of THCv genetics introduced

Front Range Biosciences® ("FRB"), a cannabis and hemp genetics platform company, became one of the first genetics providers to launch a new product line of high THCv plant varieties. This first generation product line contains more than 20% total cannabinoids, more than 8% THCv, and over 2% grassy and fruity terpenes. These new varieties yield twice the yield of typical THCv producing plants. 

This is the first THCv product line from FRB's world-renowned breeding program and expansive cannabis genetics library. This revolutionary THCv variety will pave the way for more unique consumer products, medical research and therapeutics. There is also a growing body of research linking THCv to a number of potential therapeutic benefits, including regulating tremors and seizures in ALS and Parkinson's patients, blocking fight or flight responses in PTSD, and acting as an effective analgesic for treating pain and migraines.

Challenging breed
"THCv, along with other minor cannabinoids, terpenes, and even flavonoids, have been a challenging group of traits for breeders to develop while maintaining the level of vigor and yield needed to introduce these products into the supply chain effectively," says Dr. Reggie Gaudino, VP of R&D for Front Range Biosciences. "The many years of genomics and chemistry research our team has been committed to for cannabis is allowing us to help growers and product companies do so much more with the plant than what was possible, even just a few years ago."

Growers have faced challenges producing cannabis containing high THCv content. The price of THCv has remained high due to significant lack of supply, and product availability has been extremely limited. This new class of THCv genetic products provides a timely solution to both issues, creating lucrative opportunities for cultivators and operators.